Is Soni Medicare overvalued or undervalued?

As of 17 November 2025, Soni Medicare's valuation grade has moved from attractive to risky, indicating a significant shift in its financial outlook. The company appears to be overvalued, particularly given its troubling ratios, including a PE ratio of -43.73, an EV to EBITDA of 51.80, and a ROE of -76.74%. These figures suggest that the company's earnings are not only negative but also that it is trading at a high multiple relative to its earnings before interest, taxes, depreciation, and amortization. In comparison to its peers, Soni Medicare's valuation stands out unfavorably. For instance, Apollo Hospitals, which is rated attractive, has a PE ratio of 64.41 and an EV to EBITDA of 33.85, while Max Healthcare is categorized as very expensive with a PE of 77.22 and an EV to EBITDA of 53.09. The stark contrast in these ratios highlights Soni Medicare's riskier position within the industry. Additionally, despite a remarkable year-to-date stock return of 210.97%, the recent performance has lagged behind the Sensex, which returned 8.72% over the same period. This combination of factors reinforces the conclusion that Soni Medicare is currently overvalued.